{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:05:08Z","timestamp":1791518708181,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejca.2024.114202","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T22:57:50Z","timestamp":1720220270000},"page":"114202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["\u201cSymptomatic\u201d melanoma brain metastases: A call for clear definitions and adoption of standardized tools"],"prefix":"10.1016","volume":"208","author":[{"given":"Emilie","family":"Le Rhun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carey","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson S","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Tawbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114202_bib1","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours","volume":"32","author":"Le Rhun","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114202_bib2","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/neuonc\/noac118","article-title":"Brain metastases: a society for neuro-oncology (SNO) consensus review on current management and future directions","volume":"24","author":"Aizer","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2024.114202_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101624","article-title":"Leptomeningeal metastasis from solid tumours: EANO-ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"8","author":"Le Rhun","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2024.114202_bib4","first-page":"579","article-title":"Intracranial metastases from systemic cancer","volume":"19","author":"Posner","year":"1978","journal-title":"Adv Neurol"},{"key":"10.1016\/j.ejca.2024.114202_bib5","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/cncr.33459","article-title":"Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies","volume":"127","author":"Bander","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2024.114202_bib6","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/neuonc\/noac251","article-title":"Changes in outcomes and factors associated with survival in melanoma patients with brain metastases","volume":"25","author":"Hasanov","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2024.114202_bib7","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","article-title":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","volume":"22","author":"Tawbi","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114202_bib8","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1001\/jamaoncol.2022.1928","article-title":"Brain metastasis\u2014a distinct oncologic disease best served by an integrated multidisciplinary team approach","volume":"8","author":"Moss","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2024.114202_bib9","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/S1470-2045(23)00297-8","article-title":"National Cancer Institute collaborative workshop on shaping the landscape of brain metastases research: challenges and recommended priorities","volume":"24","author":"Kim","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114202_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000763","article-title":"Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma","volume":"5","author":"Le Rhun","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2024.114202_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(23)00292-9","article-title":"Retraction and republication-TRICOTEL: defining symptomatic brain metastases in clinical trials","volume":"24","author":"Dummer","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114202_bib12","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2024.114202_bib13","first-page":"S1470","article-title":"Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study","author":"Dummer","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114202_bib14","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114202_bib15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1158\/1078-0432.CCR-22-2581","article-title":"Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases","volume":"29","author":"Wilmott","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.114202_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/science.abo7649","article-title":"Transforming the understanding of brain immunity","volume":"380","author":"Castellani","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.ejca.2024.114202_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.115","article-title":"Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series","volume":"2","author":"Banks","year":"2019","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.ejca.2024.114202_bib18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/neuonc\/nox029","article-title":"The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria","volume":"19","author":"Nayak","year":"2017","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.ejca.2024.114202_bib19","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S1470-2045(10)70294-1","article-title":"International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer","volume":"12","author":"Wefel","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114202_bib20","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114202_bib21","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/JCO.19.02767","article-title":"Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase iii trial NRG oncology CC001","volume":"38","author":"Brown","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114202_bib22","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.1016\/S1470-2045(17)30345-5","article-title":"European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma","volume":"18","author":"Pace","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114202_bib23","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/neuonc\/noac043","article-title":"Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: a joint EORTC BTG and RANO effort","volume":"24","author":"Le Rhun","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2024.114202_bib24","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114202_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/neuonc\/noz147","article-title":"Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression","volume":"22","author":"Galldiks","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2024.114202_bib26","article-title":"RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults","author":"Wen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114202_bib27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114202_bib28","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114202_bib29","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114202_bib30","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1158\/1078-0432.CCR-21-1046","article-title":"Primary analysis and 4-year follow-up of the phase iii NIBIT-M2 trial in melanoma patients with brain metastases","volume":"27","author":"Di Giacomo","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492400858X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492400858X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T12:10:02Z","timestamp":1747656602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492400858X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":30,"alternative-id":["S095980492400858X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114202","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cSymptomatic\u201d melanoma brain metastases: A call for clear definitions and adoption of standardized tools","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114202","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"114202"}}